Author

M. Nukaya

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:mouse· 5 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

S. Ronnekleiv-Kelly· 4 shared S. M. Ronnekleiv-Kelly· 3 shared A. R. Farghli· 2 shared K. A. Matkowskyj· 2 shared M. T. Walcheck· 2 shared M. Walcheck· 2 shared P. B. Schwartz· 2 shared P. Sethupathy· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

S. Ronnekleiv-Kelly

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma

R. K. Ma, P.-Y. Tsai, A. R. Farghli, A. J. Shumway, M. Kanke, J. D. Gordan, T. Gujral, K. Vakili, M. Nukaya, L. Noetzli, S. Ronnekleiv-Kelly, W. Broom, J. Barrow, P. Sethupathy

This paper identifies LINC00473 as a downstream mediator of DNAJB1-PRKACA fusion in fibrolamellar carcinoma, showing it promotes tumor growth and alters mitochondrial function.

bioRxiv · Jun 2, 2023Cancer Biology

CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma

M. Nukaya, C. Cafferty, K. Zahed, I. Yun, D. P. Al-Adra, N. A. Kazim, A. R. Farghli, M. Chan, J. D. Kratz, M. E. Berres, A. Yen, T. Gujral, P. Sethupathy, C. A. Bradfield, S. M. Ronnekleiv-Kelly

This study identifies CDK7 as a therapeutic target in fibrolamellar carcinoma by showing its activation in FLC cells and efficacy of CDK7 inhibitors in patient-derived models.

bioRxiv · Apr 22, 2023 · PreprintCancer Biology

Aryl hydrocarbon receptor knockout accelerates PanIN formation and fibro-inflammation in a mutant Kras-driven pancreatic cancer model

M. Walcheck, P. Schwartz, N. Carrillo, K. Matkowsky, M. Nukaya, S. Ronnekleiv-Kelly

bioRxiv · Feb 1, 2023 · PreprintCancer Biology

The Circadian Clock is Disrupted in Pancreatic Cancer

P. B. Schwartz, M. Nukaya, M. Berres, C. D. Rubinstein, G. Wu, J. Hogenesch, C. Bradfield, S. Ronnekleiv-Kelly

This paper demonstrates circadian clock disruption in human pancreatic cancer using bioinformatics and genetic models, showing dysregulated clock genes and accelerated cancer progression.

bioRxiv · Nov 1, 2022Cancer Biology

Chronic Jetlag Accelerates Pancreatic Neoplasia in Conditional Kras-Mutant Mice

P. B. Schwartz, M. T. Walcheck, M. Nukaya, D. M. Pavelec, K. A. Matkowskyj, S. M. Ronnekleiv-Kelly

This study shows chronic jetlag accelerates pancreatic cancer in mice with Kras mutations by affecting fibroblasts rather than cancer cells directly.

bioRxiv · Jul 18, 2022Cancer Biology

Pdx1 expression in hematopoietic cells activates Kras-mutation to drive leukemia in KC (Pdx1-Cre ; LSL-KrasG12D/+) mice

M. T. Walcheck, M. Nukaya, E. A. Ranheim, K. A. Matkowskyj, S. M. Ronnekleiv-Kelly

This study shows that Pdx1 expression in hematopoietic cells of KC mice activates KrasG12D, leading to T-ALL and thymic tumors, with 20% of mice developing the disease by 9 months.

bioRxiv · May 17, 2022Cancer Biology

Sex-dependent development of Kras-induced anal squamous cell carcinoma in mice

M. Walcheck, K. Matkowskyj, A. E. Turco, S. Blaine-Sauer, M. Nukaya, J. L. Noel, O. K. Ronnekleiv, S. Ronnekleiv-Kelly

This study shows that Kras-induced anal squamous cell carcinoma in mice is sex-dependent, driven by estrogen, and occurs independently of papillomavirus infection.

bioRxiv · Aug 4, 2021Cancer Biology